Clinical Trials

Integration Of Immunotherapy Into Adjuvant Therapy For Resected NSCLC: Alchemist Chemo-IO

NCT04267848

Adjuvant Lung Cancer Enrichment Marker Identification and Sequencing Trial (ALCHEMIST)

NCT02194738

A Randomized, Double-Blind, Placebo-Controlled Phase II Study of Oxybutynin Versus Placebo for the Treatment of Hot Flashes in Men Receiving Androgen Deprivation Therapy

NCT04600336

N0577 (CODEL): Phase III Intergroup Study of Radiotherapy with Concomitant and Adjuvant Temozolomide versus Radiotherapy with Adjuvant PCV Chemotherapy in Patients with 1p/19q Co-deleted Anaplastic Glioma or Low Grade Glioma

NCT00887146

NeMeRe, a Multi-Institutional Retrospective and Prospective Registry of Neoplastic Meningitis in Adults

NCT99999999

MammaPrint, BluePrint, and Full-genome Data Linked with Clinical Data to Evaluate New Gene EXpression Profiles: An Adaptable Registry (FLEX Registry)

NCT03053193

Eliminating Breast Cancer Surgery in Exceptional Responders to Neoadjuvant Systemic Therapy

NCT02945579

External Beam Radiation to Eliminate Nominal Metastatic Disease (EXTEND): A Randomized Phase II Basket Trial Assessing the Efficacy of Upfront Local Consolidative Therapy (LCT) for Oligometastatic Disease (2018-0349)

NCT03599765

Phase III Randomized Trial of DFP-10917 vs. Non-Intensive Reinduction (LoDAC, Azacitidine, Decitabine) or Intensive Reinduction (High and termediate Dose Cytarabine Regimens) for Acute Myelogenous Leukemia Patients in Second or Third Salvage

NCT03926624

A phase III, multicenter, randomized, open-label trial to evaluate efficacy and safety of ribociclib with endocrine therapy as an adjuvant treatment in patients with hormone receptor-positive, HER2-negative, early breast cancer (New Adjuvant TriAl with Ribociclib [LEE011]: NATALEE).

NCT03701334

FLEX: Liquid Biopsy for Breast Cancer, a Pilot Study

NCT03053193

Genomics in Oncology: Clinical Outcomes and Determinants

NCT99999999

The Spiration IBV Valve System

NCT99999999

Randomized Prospective Trial of Breast Cancer Locator Guided vs. Wire Localized Partial Mastectomy for Breast Cancer

NCT04397185

A Prospective Registry Study to Evaluate the Effect of the DCISionRT Test on Treatment Decisions in Patients with DCIS Following Breast Conserving Therapy

NCT03448926

BESPOKE Study of ctDNA Guided Therapy in Colorectal Cancer

NCT04264702

A Phase 2 Open-Label Study Evaluating Tolerability and Efficacy of Navitoclax Alone or in Combination with Ruxolitinib in Subjects with Myelofibrosis

NCT03222609

EF-32: Pivotal, Randomized, Open-Label Study of Optune® (Tumor Treating Fields, 200kHz) Concomitant With Radiation Therapy and Temozolomide for the Treatment of Newly Diagnosed Glioblastoma

NCT04471844

Inflammatory Breast Cancer (IBC) Registry

NCT00477100

A Phase 3, Multicenter, Randomized, Open-Label, Active-Controlled Study of Trastuzumab Deruxtecan (T-DXd) Versus Trastuzumab Emtansine (T-DM1) in Subjects with High-Risk HER2-Positive Primary Breast Cancer Who Have Residual Invasive Disease in Breast or Axillary Lymph Nodes Following Neoadjuvant Therapy

NCT04622319

A randomized study of head and neck radiotherapy with or without customized 3D printed oral stents

NCT04870762

Minimal Residual Disease Assessment in Colorectal Cancer (MiRDA-C)

NCT04739072

A Randomized Open-Label Phase III Study of Sacituzumab Govitecan versus Treatment of Physician s Choice in Subjects with Metastatic or Locally Advanced Unresectable Urothelial Cancer

NCT04527991

A Phase III, Open-Label, Multicenter,Randomized Study Evaluating the Efficacy and Safety of Glofitamab in Combination with Gemcitabine Plus Oxaliplatin Versus Rituximab in Combination with Gemcitabine and Oxaliplatin in Patients with Relapsed/Refractory Diffuse Large BCell Lymphoma

NCT04408638

A Phase 2, Open-Label Study to Evaluate the Safety and Antitumor Activity of CX-2009 in Advanced HR-Positive/HER2-Negative Breast Cancer and of CX-2009 as Monotherapy and in Combination with CX-072 in Advanced Triple-Negative Breast Cancer (CTMX-2009-002)

NCT04596150

A Phase 3 Randomized Study of Loncastuximab Tesirine Combined with Rituximab Versus Immunochemotherapy in Patients with Relapsed or Refractory Diffuse Large B-Cell Lymphoma (DLBCL) (LOTIS-5)

NCT04384484

A Phase 3, Randomized, Double-Blind, Adaptive, Placebo/Paclitaxel- controlled Study of AVB-S6-500 in Combination with Paclitaxel in Patients with Platinum-Resistant Recurrent Ovarian Cancer

NCT04729608

A Randomized, Double-blind, Placebo-controlled, Phase 3 Study of Pembrolizumab Plus Chemotherapy Versus Placebo Plus Chemotherapy for he Treatment of Chemotherapy-Candidate Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative (HR+/HER2-) Locally Recurrent Inoperable or Metastatic Breast Cancer (KEYNOTE-B49)

NCT04895358

A Phase 3, Randomized, Open Label Study to Compare Nivolumab plus Concurrent Chemoradiotherapy (CCRT) followed by Nivolumab plus Ipilimumab or Nivolumab plus CCRT Followed by Nivolumab vs CCRT followed by Durvalumab in Previously Untreated, Locally Advanced Non-small Cell Lung Cancer (LA NSCLC)

NCT04026412

BESPOKE Study of ctDNA Guided Immunotherapy (BESPOKE IO)

NCT04761783

SPOTLITE: ProSPective ObservaTionaL Study on the Clinical Outcomes of Surgical InTErventions in Complex Fistulizing Conditions (CPF-CD, CD-RVF, CCF)

NCT04940611

Stereotactic radiosurgery (SRS) as definitive management for a limited number of small cell lung cancer (SCLC) brain metastasis

NCT04516070

A Phase I/II Multicenter, Open-Label, Study of a Novel Bruton s Tyrosine Kinase Inhibitor, Orelabrutinib, in Patients with B-Cell Malignancies

NCT04014205

A Multicenter, Randomized, Double-Blind Phase 3 study of HBI-8000 Combined with Nivolumab versus Placebo with Nivolumab in Patients with Unresectable or Metastatic Melanoma not Previously Treated with PD-1 or PD-L1 Inhibitors

NCT04674683

A Multicenter, Open-Label Study With a Randomized Control Arm of the Efficacy, Safety, and Pharmacokinetics of Intravenously Infused Berubicin in Adult Patients With Recurrent Glioblastoma Multiforme (WHO Grade IV) After Failure of Standard First Line Therapy

NCT04762069

A Phase III, Randomized, Open-Label, Multicenter Study Evaluating the Efficacy and Safety of Adjuvant Giredestrant Compared With Physician's Choice of Adjuvant Endocrine Monotherapy in Patients With Estrogen Receptor-Positive, HER2-Negative Early Breast Cancer

NCT04961996

Shortening Adjuvant PHoton IRradiation (SAPHIRE): A Randomized Trial of Hypofractionated Versus Conventionally Fractionated Regional Nodal Irradiation for Invasive Breast Cancer

NCT02912312

A Phase III, Randomized Double-Blind, Placebo-controlled Study Evaluating the Safety and Efficacy of Magrolimab versus Placebo in Combination with Venetoclax and Azacitidine in Newly Diagnosed, Previously untreated Patients with Acute Myeloid Leukemia Who are ineligible for Intensive Chemotherapy

NCT05079230

PHASE 1 OPEN LABEL ASCENDING DOSE STUDY TO ASSESS THE FEASIBILITY AND SAFETY OF INTERMITTENT INFUSIONS OF MTX110 ADMINISTERED BY CONVECTION-ENHANCED DELIVERY (CED) AS A MONOTHERAPY OR IN COMBINATION WITH LOMUSTINE IN PATIENTS WITH RECURRENT GLIOBLASTOMA (rGBM) (MAGIC-G1 STUDY)

NCT05324501

Performance Improvement Demonstration Project: Optimizing integration of Molecular Testing in Lung and Thyroid Cancers

NCT99999999

A Phase 2, Open-Label, Single-Arm, Multicenter Study to Evaluate the Efficacy and Safety of Pemigatinib in Participants With Previously Treated Glioblastoma or Other Primary Central Nervous System Tumors Harboring Activating FGFR1-3 Alterations (FIGHT-209)

NCT05267106

EF-25 (METIS): Pivotal, open-label, randomized study of radiosurgery with or without Tumor treating Fields(TTFields) for 1-10 brain metastases from non-small cell lung cancer (NSCLC)

NCT02831959

Financial Toxicity in Diverse Cancer Populations and Care Settings

Biomarker discovery study of DS-8201a, an anti-HER2-antibody drug conjugate, in randomized phase III trials (DS8201-A-U301, U302, U303) in unresectable and/or metastatic breast cancer and in patients receiving DS-8201a as standard of care treatment

A Randomized Phase III Trial for Surgically Resected Early Stage Non-Small Cell Lung Cancer: Crizotinib versus Observation for Patients with Tumors Harboring the Anaplastic Lymphoma Kinase (ALK) Fusion Protein

NCT02201992

A Randomized Phase III Trial of Consolidation with Autologous Hematopoietic Cell Transplantation Followed by Maintenance Rituximab vs. Maintenance Rituximab Alone for Patients with Mantle Cell Lymphoma in Minimal Residual Disease-Negative First Complete Remission

NCT03267433

Change in Relative Cerebral Blood Volume as a Biomarker for Early Response to Bevacizumab in Patients with Recurrent Glioblastoma

NCT03115333

The National Myelodysplastic Syndromes (MDS) Study

NCT02775383

Phase III Trial of Observation Versus Irradiation for a Gross Totally Resected Grade II Meningioma

NCT03180268

Randomized Phase II and Phase III Studies of Individualized Treatment for Nasopharyngeal Carcinoma Based on Biomarker Epstein Barr Virus (EBV) Deoxyribonucleic Acid (DNA)

NCT02135042

Phase III Randomized Trial of Standard Systemic Therapy (SST) versus Standard Systemic Therapy Plus Definitive Treatment (Surgery or Radiation) of the Primary Tumor in Metastatic Prostate Cancer

NCT03678025

Melanoma Margins Trial (MelMarT): A Phase III, Multi-Centre, Multi-National Randomised Control Trial Investigating 1cm v 2cm Wide Excision Margins for Primary Cutaneous Melanoma

NCT03860883